Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Anishka D'souza"'
Publikováno v:
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-10 (2018)
Abstract Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/
Externí odkaz:
https://doaj.org/article/77e961727f2548b9a29cdac6061d55cd
Autor:
Maedah Veyseh, Charite Ricker, Carin Espenschied, Victoria Raymond, Anishka D’Souza, Afsaneh Barzi
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Liquid biopsies are increasingly used in the care of patients with advanced cancers. These tests are used to find mutations and other genomic alterations, quantify these findings over time, and guide treatment. It is not unexpected that germline muta
Externí odkaz:
https://doaj.org/article/3a0d0f6dbd8d47d88e74c003f97790e3
Autor:
Toni K Choueiri, David F McDermott, Jaime Merchan, Todd M Bauer, Robert Figlin, Elisabeth I Heath, M Dror Michaelson, Edward Arrowsmith, Anishka D'Souza, Song Zhao, Ananya Roy, Rodolfo Perini, Donna Vickery, Scott S Tykodi
Publikováno v:
The Lancet Oncology. 24:553-562
Autor:
Catherine Ly, Shiliang Zhang, Lauren Antrim, Nikhita Kathuria-Prakhash, Matthew Ebia, Varsha Tulpule, Anishka D'souza, Gino Kim In
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:CLO22-062
Autor:
Peter Zang, Tanya Dorff, Zhang-Xu Liu, Denice Tsao-Wei, Susan Groshen, Cheryl Kefauver, Czarina Patricio, Anishka D'Souza, Sarah Chevalier, Sumanta Pal, Diane DaSilva, Martin Kast, David Quinn
Publikováno v:
Regular and Young Investigator Award Abstracts.
Publikováno v:
Journal of Clinical Oncology. 39:265-268
Autor:
Varsha Tulpule, Irene Kang, Matthew Isaiah Ebia, Charité Ricker, Kimberly A. Miller, Anishka D'souza, Gino K. In, David R. Freyer, Jacob Stephen Thomas, Stephen Capone
Publikováno v:
Cureus
Multiple primary malignancies (MPM) are described as two or more primary tumors within the same individual. The impact of MPM on the tumor microenvironment among patients with melanoma is poorly understood. Here, we describe this unique group of pati
Publikováno v:
Kidney Cancer. 3:93-102
The treatment landscape of advanced renal cell carcinoma (RCC) is rapidly evolving. Immune checkpoint inhibitors (ICI) have now become the preferred first line treatment with the approval of nivolumab and ipilimumab combination in intermediate to poo
Autor:
Peter Zang, Karen Resnick, Travis Larsen, Shirley Ye, April Choi, Xiao Yu, Kevin Brady, Varsha Tulpule, Anishka D'souza, Gino Kim In
Publikováno v:
Journal of Clinical Oncology. 40:4530-4530
4530 Background: Immune checkpoint inhibitor (ICI) therapy has become a standard therapy in the treatment of advanced renal cell carcinomas (RCC). This has led to a proportional increase in the frequency of immune related adverse events (irAE), howev
Autor:
Khanh T. Do, Claire F. Friedman, François-Clément Bidard, Richard Bryce, Anishka D'souza, Bradley J. Monk, Adam C. ElNaggar, Lynda D. Roman, Feng Xu, Irene Brana, Kiana Keyvanjah, Edwin A. Alvarez, Funda Meric-Bernstam, Rodolfo Passalacqua, David M. Hyman, Valentina Boni, David B. Solit, Ana Oaknin, Alessandro D. Santin, Jonathan H. Goldman, Lisa D. Eli, Alshad S. Lalani
Publikováno v:
Scientia
Gynecologic oncology
Gynecologic oncology, vol 159, iss 1
Gynecologic oncology
Gynecologic oncology, vol 159, iss 1
Càncer de coll uterí; Assaig clínic; Mutant HER2 Cáncer de cuello uterino; Ensayo clínico; Mutante HER2 Cervical cancer; Clinical trial; HER2 mutant Objective: Somatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::188b242a6feeedb6adbc71f9d83353ba
https://hdl.handle.net/11351/6338
https://hdl.handle.net/11351/6338